comparemela.com

Latest Breaking News On - Harrisl rotman - Page 1 : comparemela.com

Investegate |Centessa Pharmaceuticals plc Announcements | Centessa Pharmaceuticals plc: Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2022; Provides Program Update for ZF874

Investegate announcements from Centessa Pharmaceuticals plc, Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2022; Provides Program Update for ZF874

United statesCity ofUnited kingdomHarrisl rotmanMathias hukkelhovenBristol myers squibbSaurabh sahaKristenk sheppardRegulatory affairsResearch developmentExchange commissionUpcoming program milestonesResearch development expensesCentessa predecessor groupCentessa pharmaceuticals reports financialCentessa pharmaceuticals

Centessa Pharmaceuticals plc: Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2022; Provides Program Update for ZF874

- Registrational studies of SerpinPC for treatment of Hemophilia B planned for 2H of 2022 - - Oncology pipeline advancing with novel LockBody technology - - Announces discontinuation of ZF874

United statesCity ofUnited kingdomHarrisl rotmanMathias hukkelhovenBristol myers squibbSaurabh sahaKristenk sheppardRegulatory affairsResearch developmentExchange commissionUpcoming program milestonesResearch development expensesCentessa predecessor groupCentessa pharmaceuticalsChief executive officer

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2022; Provides Program Update for ZF874

10.08.2022 - - Registrational studies of SerpinPC for treatment of Hemophilia B planned for 2H of 2022 – - Oncology pipeline advancing with novel LockBody technology – - Announces discontinuation of ZF874 for AATD – - Multiple clinical PoC readouts expected .

United statesCity ofUnited kingdomHarrisl rotmanMathias hukkelhovenBristol myers squibbSaurabh sahaKristenk sheppardRegulatory affairsResearch developmentExchange commissionUpcoming program milestonesResearch development expensesCentessa predecessor groupCentessa pharmaceuticalsChief executive officer

Investegate |Centessa Pharmaceuticals plc Announcements | Centessa Pharmaceuticals plc: Centessa Pharmaceuticals Announces Addition of Harris L Rotman, PhD, as Senior Vice President of Regulatory Affairs

Investegate announcements from Centessa Pharmaceuticals plc, Centessa Pharmaceuticals Announces Addition of Harris L. Rotman, PhD, as Senior Vice President of Regulatory Affairs

United statesCity ofUnited kingdomHarrisl rotmanSaurabh sahaKristenk sheppardHead of regulatory affairs at swanbio therapeuticsWyeth pharmaceuticalsShire pharmaceuticalsRegulatory affairsCook college at rutgers universityResearch developmentThomas jefferson universityExchange commissionCentessa pharmaceuticalsBranded business at endo pharmaceuticals

Centessa Pharmaceuticals Announces Addition of Harris L Rotman, PhD, as Senior Vice President of Regulatory Affairs

Centessa Pharmaceuticals Announces Addition of Harris L. Rotman, PhD, as Senior Vice President of Regulatory Affairs - read this article along with other careers information, tips and advice on BioSpace

United statesCity ofUnited kingdomHarrisl rotmanSaurabh sahaKristenk sheppardHead of regulatory affairs at swanbio therapeuticsWyeth pharmaceuticalsShire pharmaceuticalsRegulatory affairsCook college at rutgers universityResearch developmentThomas jefferson universityExchange commissionCentessa pharmaceuticalsBranded business at endo pharmaceuticals

vimarsana © 2020. All Rights Reserved.